性结肠炎中的巨细胞:免疫调节作用,表型转换和治疗向
Journal of innate immunity
|January 13, 2026
概括
在性结肠炎 (UC) 中,亲炎性巨细胞驱动肠道炎症和损伤. 针对这些免疫细胞为UC患者提供了有前途的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 细胞生物学 细胞生物学
背景情况:
- 性结肠炎 (UC) 涉及肠道免疫失调.
- 肠道巨细胞对于维持肠道平衡和UC病理学至关重要.
研究的目的:
- 审查肠道巨细胞在UC中的作用.
- 讨论巨细胞的起源,异质性,可塑性和UC中的调节途径.
- 评估UC的现有和新兴巨细胞向治疗方法.
主要方法:
- 在UC中对巨细胞生物学进行了全面的文献综述.
- 对信号通路的分析 (NF-κB,JAK-STAT,NLRP3炎症体).
- 评估治疗策略,包括细胞因子阻断和纳米医学.
主要成果:
- 肠道巨体在健康状况下表现出"炎症性无能性",但在UC中偏向于亲炎症的M1类表型.
- 类似M1的巨细胞分泌炎症性细胞因子 (TNF-α,IL-1β,IL-6,IL-12/23),ROS/RNS和MMP,损害了上皮屏障.
- 关键的调节通路,如NF-κB,JAK-STAT和NLRP3炎症体,都与UC巨细胞功能有关.
结论:
- 了解巨细胞的可塑性和异质性是开发有针对性的UC疗法的关键.
- 需要单细胞和空间转录组学来定义人类UC中的巨细胞子集.
- 开发精确的免疫调节策略和生物标志物可以改善UC患者的护理.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Drugs for Treatment of Ulcerative Colitis in IBD
452
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
452
Inflammatory Bowel Disease IV: Pharmacological Management
496
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
496
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Inflammatory Response
15.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484


